Melanoma patient details mRNA vaccine trial journey — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Merck and Moderna announced promising late-stage results in August for combining mRNA cancer vaccine intismeran autogene with Keytruda for melanoma, but the article notes such data don't show what treatment means for individual patients.
- Gary Keblish, a public schoolteacher diagnosed with high-risk melanoma in 2019, shared his experience virtually at the STAT Summit in Boston on Thursday.
- Keblish was treated by Jeffrey Weber, deputy director of NYU Langone's Perlmutter Cancer Center and co-leader of its Clinical Melanoma Program, after being randomized into the trial's treatment arm.
- Keblish experienced neuropathy that affected his physical activity, judgment, and emotional outlook, requiring family and doctors to "read between the lines" to push him in the right direction.
- Six years after his tumor was removed, Keblish is still teaching and never had to leave the classroom, framing his journey throughout with "The Magic School Bus" metaphors.
Why it matters: For a treatment class that on August trial readouts communicated efficacy statistics, Keblish's account fills the human gap with concrete details about neuropathy's toll and the emotional stakes of being randomized into the treatment arm. Oncologists and drug developers get a reminder that survival curves don't capture the lived experience of riding out side effects, which matters as mRNA cancer vaccines move toward potential approval and broader use.
Ask SkimNews
